TPM add-on long-term open-label treatment was evaluated in 76 patients with Partial Refractory Epilepsy over a mean period of 12 months. The mean TPM dosage was 418+168 mg/day. About 30% of patients achieved >50% seizure reduction; 10% of patients were seizure-free. 13 (15%) patients discontinued TPM because of adverse events. Findings from this study show that TPM is ah useful agent for long-term seizure control, with some patients becoming seizure-free.
|Translated title of the contribution||Long-term evaluation of the efficacy and tolerability of topiramate as add-on therapy in patients with refractory partial epilepsy|
|Number of pages||2|
|Journal||Bollettino - Lega Italiana contro l'Epilessia|
|Publication status||Published - 2001|
ASJC Scopus subject areas
- Clinical Neurology